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Summary The androstenedione derivative, exemestane (FCE 24304), is a new orally active irreversible
aromatase inhibitor. Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate
the activity of four low exemestane doses in reducing oestrogen levels. The drug's tolerability and clinical
efficacy were also assessed. Exemestane was orally administered to four consecutive groups at daily doses of
25, 12.5, 5 and 2.5 mg, and the changes in oestrogen, gonadotrophins, sex-hormone binding globulin and
dehydroepiandrosterone sulphate levels were evaluated. Drug selectivity was studied by measuring 17-
hydroxycorticosteroid urinary levels. After 7 days of treatment, mean oestrone and oestradiol levels had
decreased by respectively 64% and 65% (a decrease which was maintained over time); in the 2.5 mg group,
oestrone sulphate levels also decreased by 74%. Gonadotrophin levels were significantly higher, whereas no
changes in the other serum hormone levels or any interference with adrenal synthesis were detected. Treatment
tolerability was satisfactory: nausea and dyspepsia were reported in 16% of patients. The overall objective
response rate was 18%. In conclusion, exemestane is effective in reducing oestrogen levels at all of the tested
doses and shows interesting clinical activity.
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Aromatase inhibition represents one of the main endocrine
treatment options in post-menopausal metastatic breast
cancer, and irreversible aromatase inhibitors (steroidal com-
pounds structurally related to the natural substrate and-
rostenedione) have recently been developed.
The first ofthese to be used in clinical practice was formes-
tane (Coombes et al., 1984; Goss et al., 1986; Hoffken et al.,
1990; Pickles et al., 1990; Stein et al., 1990) for which,
although it has been described as a 'suicide inhibitor' because
of its mechanism of action, possible interference with growth
factors has also been evaluated (Reed et al., 1992; Ferrari et
al., 1994). In our experience, it has been found to lead to a
significant reduction in oestrogen levels and to have good
clinical efficacy (Bajetta et al., 1993, 1994). The preferred
route of administration is parenteral because of the drug's
rapid and extensive hepatic metabolism; the oral formulation
requires higher doses to be effective (Dowsett et al., 1989).
Although local side-effects were mild and infrequent in our
experience, other authors have described local pain at the
injection site in approximately 14% of patients (Coombes et
al., 1992).
In an attempt to identify an aromatase inhibitor with
better oral activity than formestane, a new steroidal
derivative, exemestane (FCE 24304), has been evaluated
(Guidici et al., 1988; di Salle et al., 1990). In animal mam-
mary tumour models, this has been found to be effective in
inducing tumour regression when used either orally or by the
subcutaneous route (Zaccheo et al., 1989a), and these results
have been confirmed in a model of post-menopausal breast
cancer in ovariectomised rats bearing 7,12-dimethylben-
zanthracene-induced mammary tumours (Zaccheo et al.,
1989b). A Phase I study using a single oral dose ranging from
0.5 to 800 mg was conducted in 29 healthy post-menopausal
volunteers (Evans et al., 1992); the reduction in plasma
oestrone (El), oestradiol (E2) and oestrone sulphate (E,S), as
well as in urinary total El and E2 was taken as evidence of
aromatase inhibition. A dose-related inhibitory effect on
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oestrogen biosynthesis was observed at doses of 5-25 mg.
The lowest effective dose was found to be 5 mg, which
reduced plasma oestrogen and urinary El levels to 50% of
baseline values by day 3; maximal suppression was obtained
with the 25 mg dose, considered to be the minimally effective
dose producing maximal oestrogen reduction (di Salle et al.,
1992; Evans et al., 1992).
On the basis of these data, we investigated four low
exemestane doses administered daily to post-menopausal
patients with advanced breast cancer; the present paper
reports their endocrine effects, tolerability and clinical
efficacy.
Materials and methods
Patient selection
Fifty-six consecutive post-menopausal patients pretreated for
advanced breast cancer entered the study, which was con-
ducted at the Medical Oncology Division B of Milan's
Istituto Nazionale per lo Studio e le Cura dei Tumori.
Patients were considered eligible only if they had a diag-
nosis of advanced breast cancer with measurable disease, a
performance status of 0-2 (ECOG scale), and positive
oestrogen receptor (ER) status as assessed on the primary
tumour or metastases. Receptor levels were measured using
the dextran-coated charcoal method, and values > 10 and
25 fmolmg-' of cytosol protein were considered positive for
ER and progesterone receptors (PgR) respectively; otherwise
an immunostaining technique was used. If the receptor status
was unknown, a disease-free interval (DFI) of more than 2
years was considered. Post-menopausal status was defined as:
1 year or more since spontaneous menopause; 2 years or
more since drug-induced amenorrhea in patients older than
50 years; in the case of patients aged less than 50 years,
follicle stimulating hormone (FSH) and luteinising hormone
(LH) levels had to be within the post-menopausal range.
Patients who had undergone bilateral surgical oophorectomy
were also considered. The patients had to have received a
previous systemic anti-cancer therapy which had been stop-
ped at least 3 weeks before their entry into the study. The
wash-out period was extended up to 6 weeks if drugs in
depot formulation had been previously used.Exemestane inadvanced breast cancer $W N Zilembo etal
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Patients were excluded if they had endocrine disorders or
other concurrent malignant disease or if they were taking
concomitant anti-cancer treatments (with the exception of
limited radiotherapy fields in the presence of other evaluable
lesions). Patients were also considered ineligible if they had
significant renal or hepatic dysfunction (creatinine> 1.25
times the upper limit of normal, bilirubin> 1.25 times the
upper limit of normal and/or transaminases> 1.25 times the
upper limit of normal). Patients with WBC and platelet
counts of respectively <3000 mm-3 and < 100 000mm-'
were excluded, as were those who showed more than one-
third liver involvement, lymphangitic lung metastases or
brain deposits. Staging and tumour response were defined by
means of physical examination, bone scan, chest and skeletal
radiographs, liver echography or computed tomographic
scan, whole blood cell counts and blood chemistry. These
examinations were performed at the beginning of the study,
after 56 days as first evaluation, and then every 2 months.
Signs, symptoms and toxicity were evaluated according to
National Cancer Institute (Bethesda) criteria, and clinical
response according to UICC criteria (Hayward et al., 1977).
All of the patients gave their informed consent and the study
was approved by the local bioethics committee.
Study design and treatmentplan
The study considered four consecutive treatment groups of
14 patients each. Exemestane was supplied by Pharmacia
(Farmitalia Carlo Erba) in 2.5, 5, 12.5 and 25 mg capsules,
and was taken p.o. at 12 a.m. daily. The first 14 patients
entering the study received the highest dose of 25 mgday-1;
the next two groups of 14 patients respectively received 12.5
and 5mgday-'; the final 14 patients received 2.5mgday-'.
The patients were seen in an out-patient setting on the day
before treatment was started, when they were examined and
staged. On the first day of treatment, blood samples were
taken at 9 a.m. for endocrine studies and an overnight 12 h
urine sample was also collected. The patients were subse-
quently examined on days 7, 14, 28 and 56, when toxicity
was assessed and further blood samples were taken for
haematological, biochemical and endocrine studies; urine
samples were also collected on days 14, 28 and 56. Tumour
response was also evaluated on day 56. Blood was collected
at room temperature, allowed to clot, centrifuged at 3000g
and then stored at -20°C until assay. Oestrogen, LH, FSH,
sex-hormone binding globulin (SHBG) and dehydroepiand-
rosterone sulphate (DHEAS) serum levels were all measured
when the accrual for each dose group had been completed. In
addition, while the study was ongoing and owing to the
increasing importance given to EIS in the endocrinological
evaluation of women with breast cancer in the recent
literature, we decided to test EIS in order to complete the
profile of drug activity. Unfortunately, for technical reasons,
E,S levels could only be assessed in the last group ofpatients.
The patients were instructed how to collect overnight 12 h
urine and each of them was given a standard plastic tube
(volume 1 L, Kartell, Milan, Italy); in order to check that the
patients collected all urine volume, they were asked to com-
plete a personal card indicating when and how many times
urine had been collected, especially during the night. On
examination days, the patients had to return the tube and the
card, which was checked by nursing staff. Thereafter, the
volume ofurine was measured and a 20 ml sample was taken
and kept frozen at -20°C until analysis for 17-hydroxycor-
ticosteroids (17-OHCS). If their disease had not progressed
after 56 days of treatment, the patients continued receiving
the same dose of exemestane; treatment was stopped at the
time of documented disease progression.
Hormonal measurements
All hormone assays were performed by the Laboratory of
Endocrinology at Milan's Istituto Nazionale per lo Studio e
la Cura dei Tumori.
Serum El and E2 levels were measured by means of radio
immunoassay (RIA) after liquid phase extraction and
chromatographic separation. 3H-El (Bio-Merieux) and 3H-E2
(Bio-Merieux) were added to each serum sample (3 ml) as
recovery markers and extracted with 11 ml diethyl ether. The
serum phase was frozen and the ether extract decanted into
clean tubes and dried under nitrogen. This free steroid-
containing fraction was reconstituted in 1 ml of isooctane
saturated with ethyleneglycol before proceeding to the
chromatographic separation of El and E2 on a Celite column
[Celite Supelco mixed with ethyleneglycol (2:1, w/v)]. In the
chromatographic step, the redissolved sample was applied to
the column and successive elutions with increasing concentra-
tions of ethylacetate in isooctane (0, 18 and 40%) were
collected. The fractions containing El (18% ethylacetate) and
E2 (40% ethylacetate) were evaporated under nitrogen and
the dried samples redissolved in 5001lI of the appropriate
incubation buffer. A duplicate aliquot of this suspension
(100 ,l for El and 50 ,lI for E2) was subjected to the specific
RIA procedure, and a further aliquot (200pI for El and for
E2) to final recovery, which ranged between 75% and 85%
for El and between 70% and 80% for E2. The blank deter-
mined in the bidistilled water sample prepared in the same
way as the serum sample did not exceed 2 pg per tube for E,
and 0.25 pg per tube for E2. The commercially available RIA
kits 3H-El (Bio Merieux) and '251-E2 (Clinical Assay) were
used to determine El and E2 levels. The standard curve ofthe
E2 kit (supplied in serum) was substituted with a standard
curve in buffer. The sensitivity of the assay was 1 pgml-' for
E2 and 4 pg ml-' for El. The intra-assay coefficients of varia-
tion (CVs) (n =9) for E2 were 3.1% and 1.8% at 25 pgml-'
and 14 pg ml-' respectively; the intra-assay CVs for El were
8.1% and 9.0% at 39pgml-' and 21 pgml-' respectively.
The interassay CV was 7.7% for El and 6% for E2 (n = 11).
Serum EIS levels were measured by means of RIA after
enzyme hydrolysis, liquid phase extraction and chromato-
graphic separation on a Celite column. A serum sample of
3 ml was extracted with 11 ml of diethyl ether to eliminate
free steroids, and the ether phase discarded. 3H-EIS (Du Pont
Nen Net-203 Estrone Sulphate, ammonium salt [6,7-3H(N)])
was added to the aqueous phase (containing E,S) as a
recovery marker, and the solution was submitted to enzyme
hydrolysis with 2mg of sulphatase (Sigma 9626 type H-I)
and 3 ml 0.2 M acetate buffer (pH 4.8) and then incubated for
22 h at 45°C. Extraction, chromatographic separation and
RIA were carried out as for El. The final recovery was
70-80%. The blank determined in the bidistilled water
sample prepared in the same way as the serum sample did
not exceed 4pg per tube. The sensitivity of the assay was
8.5 pg ml-'; the intra-assay CV was: 6.1% at 191 pg ml-'
(n = 9) and 5.7% at 425 pgml (n = 7), and the interassay
CV was 11%.
Immunoreactive assays were used to determine serum
DHEAS, LH, FSH and SHBG levels.
The performance data for these assays were as follows:
DHEAS (Sclavo Technogenetics), sensitivity 50 ng ml-',
intra-assay CV 6.3% and interassay CV 7.1%; LH (Ares
Serono), sensitivity 0.5mUImlm', intra-assay CV 1.1% and
interassay CV 2.9%; FSH (Ares Serono), sensitivity 0.5 mUl
ml-', intra-assay CV 1.6% and interassay CV 1.7%; SHBG
(Orion Corporation), sensitivity 6.25 nmol 1-, intra-assay
CV 3.5% and interassay CV 7.1%. All of the samples from
individual patients were analysed in the same run of the
assay procedure and all of the assays were carried out in
duplicate. Urinary adrenal glucocorticoid metabolite levels
(jcmol 12 h'-) were determined by means of gas chromato-
graphy according to the method of Murphy and West (1966).
Statistical methods
Except for 17-OHCS, the original values were log-trans-
formed before performing the analyses.
Descriptive statistics (means and 95% confidence intervals)
were computed for all hormone levels by dose levels and
times of assessment.Repeated-measurement analyses of variance (ANOVA)
were performed to assess the effect of log(dose), time and
time x log(dose) interaction factors on hormone levels. The
F-tests on within-subject effects were adjusted as described by
Huynh and Feldt (1976). The adopted significance level was
5%.
The best overall response calculated from the time of its
onset to the time of progression was considered for the
duration of response. Time to treatment failure (TTF) was
defined as the period from the date of starting treatment to
the date of progression, and analysed using the Kap-
lan-Meier method.
Results
Patient characteristics
Between January 1992 and February 1993, 56 patients
divided into four groups of 14 patients each were sequentially
treated with exemestane. All of the patients were assessable
in terms of their endocrinological profile and clinical res-
ponse; their main characteristics are shown in Table I. The
four groups were homogeneous in terms of age, ER status
and the sites and extent ofdisease. PgR status was positive in
30, negative in seven and unknown in 19 patients. Approx-
imately 54% of the patients were both ER and PgR positive.
The DFI was long in the majority ofpatients, being less than
2 years in 13; only one patient (in the 12.5 mg group) had no
DFI. In 27 patients, spontaneous menopause had lasted for
more than 5 years. All of the patients had previously received
Table I Main patient characteristics
25mg 12.5mg 5mg 2.5mg
No. ofpatients 14 14 14 14
Median age 61 60 63 56
(range) (40-75) (37-78) (49-75) (34-68)
ER+ 10 11 11 11
ER (fmol mg-1):
10-50 5 3 4 5
>50 4 7 5 4
Unknown 4 3 3 3
ER+/PgR+ 6 9 9 6
Spontaneous menopause 9 7 9 7
Oophorectomy 2 5 4 4
Drug-induced menopause 3 2 1 3
Site ofmetastatic disease:
Soft tissue 6 3 7 6
Viscera 9 10 7 7
Bone 11 9 5 9
Number of sites:
1 5 7 9 6
>,2 9 7 5 8
Previous endocrine therapies
for metastatic disease:
1 treatment 10 8 10 11
> 1 treatment 4 4 3 3
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tamoxifen (53 patients for metastatic disease, 12 patients also
as adjuvant treatment). Twenty-three patients had previously
received chemotherapy for advanced disease, six of whom
had been treated with two or more regimens.
Endocrine effects
The serum values of El and E2 before and during treatment
with each exemestane dose are reported in Table II. Max-
imum suppression was reached on day 7 and maintained
thereafter. Figures 1 and 2 show the changes in El and E2
expressed as relative changes vs baseline values. There was
also a progressive decrease in SHBG levels over time (Table
III). Serum DHEAS (Table III) and urinary 17-OHCS (Table
IV) levels remained unchanged during treatment at all of the
tested doses. A tendency to increase over time was observed
for gonadotrophin levels (Figure 3). The trend of E1S serum
levels in the 2.5 mg group was in line with those of El and E2
(Table V, Figure 4).
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Figure 1 Relative changes vs baseline in serum El levels during
treatment for each exemestane dose in all treated patients.
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Figure 2 Relative changes vs baseline in serum E2 levels during
treatment for each exemestane dose in all treated patients.
Table II Serum E, and E2 levels (pmol l-) during exemestane therapy, expressed as means
El 25mgday-' 12.5mgday-' 5mgday-' 2.5mgday '
Day 0 71.0 (57.2-88.1)a 91.9 (72.5-116.7) 98.4 (78.1-123.9) 75.2 (64.9-87.2)
7 28.4 (24.1-33.4) 29.7 (25.1-35.1) 30.8 (25.2-37.7) 30.1 (25.3-35.9)
14 34.4 (29.4-40.2) 30.9 (25.9-36.8) 30.6 (24.7-37.8) 33.1 (28.4-38.5)
28 37.6 (32.7-43.1) 32.4 (25.1-41.8) 32.1 (26.9-38.2) 35.4 (30.2-41.5)
56 35.5 (30.2-41.7) 35.7 (29.7-42.9) 35.9 (29.8-43.4) 35.8 (30.2-42.3)
E2
Day 0 15.3 (12.6-18.5) 18.9 (14.6-24.4) 20.6 (14.9-28.6) 12.6 (10.9-14.6)
7 5.2 (4.8-5.5) 5.8 (5.0-6.7) 6.2 (5.3-7.2) 5.9 (5.4-6.6)
14 5.3 (5.1-5.9) 5.8 (5.0-6.7) 5.7 (4.9-6.5) 6.0 (5.3-6.8)
28 5.5 (5.1-6.0) 5.9 (5.1-6.9) 6.3 (5.4-7.4) 6.0 (5.4-6.5)
56 5.3 (4.9-5.8) 6.3 (5.4-7.4) 6.4 (5.4-7.6) 6.3 (5.6-7.0)
'95% confidence interval in parentheses.0-k Exemestane in advanced breast cancer 9 N Zilembo etal
Table III Serum SHBG (nmol I') and DHEA-S (ngml-') during exemestane therapy, expressed as means
SHBG 25 mgday-' 12.5 mg day- 5mgday-' 2.5mgday-'
Day 0 60.7 (49.7-74.1)a 64.0 (52.5-78.1) 78.1 (53.4-114.0) 54.1 (38.5-76.1)
7 52.0 (42.2-64.1) 60.2 (49.9-72.6) 81.0 (54.7-120.1) 52.9 (37.9-73.9)
14 48.5 (38.3-61.5) 53.4 (43.5-65.5) 76.9 (50.2-117.8) 47.9 (34.6-66.3)
28 41.9 (30.8-57.0) 50.9 (42.1-61.6) 67.2 (43.2-104.4) 44.6 (32.8-60.5)
56 35.3 (25.3-49.3) 47.5 (37.6-59.9) 61.8 (41.7-91.6) 40.9 (30.2-55.6)
DHEA-S
Day 0 868.5 (610.9-1234.6) 886.0 (655.5-1197.6) 979.0 (721.8-1327.9) 1076.1 (811.6-1426.8)
7 960.5 (678.5-1359.6) 710.4 (501.7-1006.1) 878.6 (637.1-1211.6) 1006.1 (756.7-1337.6)
14 963.6 (676.9-1371.6) 725.9 (502.4-1048.9) 803.9 (611.1-1057.7) 1060.5 (806.2-1394.9)
28 984.6 (657.9-1473.5) 736.8 (521.4-1041.3) 791.4 (544.5-1150.4) 1088.2 (835.1-1418.0)
56 1033.6 (680.8-1569.2) 685.5 (471.3-996.9) 807.2 (578.7-1125.9) 1060.9 (815.8-1379.6)
'95% confidence interval in parentheses.
Table IV Urinary 17-OHCS (jimol 12 h-') during exemestane
therapy, expressed as means
17-OHCS 25mgday-' 12.5 mgday-' 5 mgday-' 2.5mgday-'
Day 0 5.1 (4.3-6.0)a 6.8 (4.9-8.6) 5.8 (3.7-7.9) 6.3 (4.8-7.9)
14 5.7 (4.3-7.1) 6.8 (5.4-8.2) 5.7 (3.8-7.7) 5.4 (4.4-6.5)
28 5.2 (4.3-6.0) 5.3 (4.2-6.4) 4.9 (3.5-6.3) 5.7 (4.2-7.3)
56 5.1 (4.0-6.2) 5.9(4.4-7.5) 5.5(4.0-6.9) 4.9(3.8-6.0)
'95% confidence interval in parentheses.
Table V Serum EIS (pmol I1) during exemestane therapy, expressed
as means (assay performed only in 2.5 mg group)
E,S 2.5mg day-'
Day 0 606.2 (475.4-773.0)a
7 158.9 (124.6-202.7)
14 164.0 (131.1-205.2)
28 149.9 (125.6-179.0)
56 189.6 (148.3-242.6)
'95% confidence interval in parentheses.
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Figure 3 Changes in serum LH and FSH (mIU ml-') levels
during treatment for each exemestane dose, expressed as the
mean for all treated patients.
Between-group comparisons of baseline hormone values
showed no difference for any hormone except E2 (P = 0.024),
with the E2 baseline values being lower in the 2.5 mg group.
At ANOVA, a significant interaction time x log(dose)
(P = 0.0476) was found only for E2, the degree of suppres-
sion appearing to be less for the lower dose. A significant
time factor effect was found for the suppression ofEl and E2
(P<0.0001). E,S in the 2.5 mg dose group was also
OU- 0-
.2 60-
m 40 -
201-
0 7 14
Days
28 56
Figure 4 Relative changes vs baseline in serum E,S levels during
treatment in the 2.5 mg group as a whole.
decreased (P<0.0001), whereas there was a significant in-
crease in LH (P = 0.0375) and FSH (P = 0.0046). The levels
of none of the other hormones significantly changed during
treatment.
Clinical toxicity
The tolerability of each exemestane dose was highly satisfac-
tory. There were no serious side-effects which could be
attributed to the drug, and no patient had to discontinue
treatment. Most of the symptoms were mild (grade 1 NCI)
and transient. The main side-effects involved the gastrointes-
tinal system: nausea, abdominal pain and diarrhoea in
respectively 12.5%, 7% and 3.6% of the patients. Hot
flushes, an allergic reaction and dizziness were reported by
one patient each; two patients experienced headache. No
haematological or biochemical toxicity was observed at any
dose level. In one patient treated with exemestane 12.5 mg,
atrial arrhythmia (grade 2 NCI) occurred.
Control of tumour growth
All of the 56 patients were evaluable and, irrespective of
exemestane dose, there was an overall response rate of 18%
(10/56). Two patients on exemestane 5 mg achieved a com-
plete response lasting 11 and >20 months respectively. They
both had positive receptors, spontaneous menopause lasting
more than 5 years and only skin disease. Partial responses
were achieved at the other three doses (three at 25 mg, two at
12.5 mg and three at 2.5 mg), with a median duration of 13
months (range 2-18+). Soft tissue lesions represented the
most responsive sites (14/32); only two patients with bone
disease responded, and one patient affected by liver meta-
stasis achieved a partial response lasting 14 months. Stable
disease with a median duration of 6 months (range 4-27)
was obtained in 27 cases; the remaining 19 patients
experienced disease progression. The TTF is given in Figure
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Figure 5 Time to treatment failure for all entered patients;
n = number of patients.
Discussion
Exemestane is a novel orally active irreversible aromatase
inhibitor and our study shows its effectiveness in suppressing
both serum El and E2 levels when given in repeated doses. A
significant reduction in serum EIS oestrogen levels was also
obtained with the lowest dose of 2.5 mg. The difference in the
percentage of E2 reduction obtained with the lowest dose
does not seem to be due to any lesser efficacy in inhibiting E2
synthesis, but more probably to the lower E2 baseline values
of these patients. Our data also show an effective reduction
ofEIS levels in the 2.5 mg group, similar to that observed by
Evans et al. (1992) using higher single doses.
A statistically significant increase in serum LH and FSH
levels was observed during treatment, a finding which has
already been reported in other studies using orally
administered aromatase inhibitors (Dowsett and Coombes,
1994). This increase is probably the result of a feedback
mechanism due to the reduction in circulating oestrogen
levels that stimulates the pituitary secretion of gonado-
trophins also in post-menopausal women.
It is known that SHBG reflects the oestrogen-androgen
balance as its synthesis is stimulated by oestrogens and
inhibited by androgens. In post-menopausal women, SHBG
is mainly a marker of androgenic activity. In our study, we
found some decrease in SHBG (although this was not statis-
tically significant) and so our data do not support the and-
rogenic activity of the drug. A fall in SHBG has also been
shown following high oral doses of formestane (Dowsett and
Coombes, 1994), and has been explained by the rapid in-
crease in drug levels in the liver (the site of SHBG synthesis)
following oral absorption. This has not been previously
reported for the parenteral administration, of even high
doses, probably owing to the short duration of the hormonal
study (Goss et al., 1986); in a previous experience, we
observed a significant decrease in SHBG in patients receiving
formestane i.m. but only from the second month of treatment
onward (Zilembo et al., 1994). The effects of all of the
exemestane doses persisted over time and appeared to be
greater than those we have previously described for the other
steroidal aromatase inhibitor formestane (Bajetta et al.,
1994) which, in comparison with baseline, led to an
average decrease in E2 serum levels of 40% after 15 days
that remained subsequently unchanged, with no difference
between the two doses of 250 and 500 mg i.m. every 2 weeks.
The efficacy of exemestane in reducing oestrogen levels
appears to be lower than that of synthetic derivatives such as
letrozole and vorozole, which are capable of reducing oest-
rogen levels to undetectable levels. In a phase I study with
letrozole, Iveson et al. (1993) found that El and E2 plasma
levels were suppressed to below the detection limit of the
assays regardless of the doses (0.1, 0.5 and 2.5 mg p.o.
day-'). The same result was obtained using racemic vorozole
at once daily doses of 2.5 or 5 mg (Borms et al., 1991). In
both treatment arms, plasma E2 levels dropped to below the
detection limit of the assay within 1 month of treatment.
Although the reduction in circulating oestrogen levels is con-
sidered to be an expression of the drugs' effectiveness, no
clinical relationship has been found (i.e. the higher the oest-
rogen reduction, the greater the clinical response), and so it is
likely that these drugs have more than one mechanism of
action. Our data confirm the selectivity of exemestane
because no effect on adrenal steroidogenesis was documented
by the 17-OHCS urinary excretion measurements.
In our experience, exemestane is a well-tolerated endocrine
treatment for advanced breast cancer patients; even the
gastrointestinal symptoms which are generally more frequent
with oral formulations were reported by only 16% of the
patients, and were transient, very mild and not dose related.
In terms of clinical efficacy, our response rate appears to
be quite low but, in our opinion, this may be due to the large
number of previous treatments. In any case, it was partic-
ularly encouraging that two complete responses were
obtained, and that three partial responses were obtained with
the lowest dose; furthermore, a good number of patients
(27%) achieved disease stabilisation lasting at least 6 months.
In conclusion, we think that exemestane may be a useful
option in the management of endocrine-dependent advanced
breast cancer, and that the good tolerability of the orally
administered drug may increase the number of patients
suitable for treatment with aromatase inhibitors.
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